Psoriasis Psoriasis, Chronic plaque type psoriasis
Conditions
Interventions
cannabidiol (CBD) dose 30 mg per dose, 0.3 ml, per oral, twice a day, total duration of 12 weeks,Placebo dose, 0.3 ml, per oral, twice a day, total duration of 12 weeks
cannabidiol (CBD),Placebo
Sponsors
National Research Council of Thailand (NRCT)
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: - Chronic plaque type psoriasis patients - Age 18-80 years old - No change of systemic treatment with in last 1 month
Exclusion criteria
Exclusion criteria: - Current biologic therapy - Active psychiatric problem with in last 1 year - Active hepatic or renal diseases - Pregnancy or lactation - Allergy to cannabidiol (CBD) or CBD derivatives
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of psoriasis at 12 weeks after end of the intervention Psoriasis Area Severity index | — |
Secondary
| Measure | Time frame |
|---|---|
| Itching at 12 weeks after end of the intervention visual analog scale of itch,Quality of life at 12 weeks after end of the intervention Dermatology Life Quality Index ,Depression/anxiety/stress at 12 weeks after end of the intervention Depression anxiety stress scales,Sleep quality at 12 weeks after end of the intervention the Pittsburgh sleep quality index,Sleep efficiency at 12 weeks after end of the intervention Sleep efficiency percentage | — |
Countries
Thailand
Contacts
Public ContactWanjarus Roongpisuthipong
Navamindradhiraj university
Outcome results
None listed